Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Respiratory indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Lung cancer presentation and diagnostic pathway

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Purpose and principles

Recognise suspected lung cancer promptly and sequence imaging, tissue, staging and fitness assessment so each test answers a treatment decision without avoidable duplication or delay.

Lung cancer may present through symptoms, an incidental scan, screening or an emergency complication. Primary care and acute clinicians should act on unexplained persistent features and use NICE NG12 criteria, while avoiding false reassurance from a single normal radiograph. The diagnostic pathway has three linked outputs: establish pathological type, establish anatomical and biological stage, and establish treatment fitness. These should be planned together at a lung multidisciplinary meeting or by the lung diagnostic team so that one procedure can answer several questions and no high-risk biopsy is performed without knowing how the result will change care.

CT anatomy determines the next step. A peripheral lesion may suit image-guided sampling; an endobronchial lesion may be reached at bronchoscopy; PET-positive mediastinal nodes may need EBUS or EUS confirmation; and a safely accessible distant lesion can both diagnose metastatic cancer and establish stage. Pathology must distinguish small-cell from non-small-cell disease and, within NSCLC, obtain the predictive biomarkers required by current NHS genomic and NICE treatment pathways. Communicate uncertainty and timescales, address smoking without blame, and provide a named contact because the interval between suspicion and treatment is clinically and psychologically demanding.

Key points

  • Persistent or unexplained haemoptysis, cough, breathlessness, chest or shoulder pain, weight loss, hoarseness, clubbing, lymphadenopathy or recurrent focal infection can signal lung cancer.
  • Follow NICE suspected-cancer referral criteria: urgent chest imaging or pathway referral is driven by age, smoking history, symptom combinations and abnormal imaging, not by a single universal presentation.
  • A normal chest radiograph does not exclude central, small or hidden lung cancer when clinical concern persists; review the image and escalate according to the whole presentation.
  • Contrast-enhanced chest CT generally precedes biopsy because it defines the primary lesion, nodes, metastases and the safest procedure likely to diagnose and stage in one sequence.
  • Choose the least invasive test that provides adequate tissue and the highest stage: accessible metastasis, EBUS or EUS, bronchoscopy, image-guided biopsy or surgery each fits a different map.
  • Preserve enough material for histological subclassification, PD-L1 and genomic testing when non-small-cell lung cancer is possible; inadequate tissue can delay or misdirect systemic treatment.
  • Staging intensity should match potentially curative treatment: PET-CT, invasive nodal sampling and brain imaging are chosen because their results would change the plan.

Indications, selection and cautions

Local airway symptoms

New persistent cough, change in a chronic cough, haemoptysis, wheeze localised to one area, dyspnoea or recurrent pneumonia in the same lobe warrants structural investigation.

Local invasion

Hoarseness, unilateral diaphragmatic elevation, chest-wall pain, Horner syndrome, superior vena cava obstruction or a persistent pleural effusion suggests extension beyond a simple parenchymal nodule.

Systemic and metastatic features

Weight loss, anorexia, fatigue, bone pain, focal neurological symptoms, seizures or pathological fracture may dominate and should trigger site-specific urgent assessment as well as chest investigation.

Paraneoplastic presentation

Hyponatraemia, hypercalcaemia, proximal weakness, neuropathy, thrombosis or unexplained clubbing may be the first clue, but alternative and medication-related causes still require assessment.

Emergency diagnosis

Massive haemoptysis, acute airway obstruction, symptomatic superior vena cava obstruction, malignant pericardial effusion, spinal cord compression or severe hypercalcaemia needs immediate stabilisation beside cancer work-up.

Radiological suspicion

A spiculated mass, hilar enlargement, lobar collapse, persistent focal consolidation, pleural nodularity or unexplained effusion should prompt urgent contrast CT and lung-team review.

Red flags requiring action

  • Life-threatening haemoptysis requires airway, oxygenation, haemodynamic resuscitation and urgent interventional or surgical coordination before the routine diagnostic sequence.

Method and interpretation

  1. 01
    Chest radiographFirst step
    Why
    Provide rapid initial imaging for symptom-triggered suspected lung cancer.
    Interpretation and limitations
    Look for a mass, hilar change, collapse, persistent consolidation or effusion; a normal film cannot overrule ongoing high clinical concern and should not end assessment automatically.
  2. 02
    Contrast-enhanced CT chest and upper abdomen
    Why
    Map the primary tumour, lymph nodes, pleura and common metastatic sites before biopsy.
    Interpretation and limitations
    Use anatomy to choose a procedure that gives diagnosis and maximal stage with the least risk; CT nodal size alone is insufficient for definitive mediastinal staging.
  3. 03
    Histology and cytology
    Why
    Confirm malignancy and classify small-cell, squamous, adenocarcinoma or another tumour.
    Interpretation and limitations
    Request adequate handling for morphology and immunohistochemistry, and conserve tissue for predictive testing; a non-diagnostic sample returns to MDT rather than proving benignity.
  4. 04
    EBUS-TBNA or EUS-guided sampling
    Why
    Sample mediastinal or hilar nodes with lower invasiveness than surgical staging.
    Interpretation and limitations
    Target nodes in a sequence that avoids contamination of a lower stage, and interpret negative findings against PET-CT risk and sampling adequacy.
  5. 05

Clinical next steps

01SUSPECTMove from symptom to urgent assessmentFirst stepNICE referral criteria, concerning persistent symptoms, abnormal chest imaging or a compatible paraneoplastic syndrome.+
  1. 1Take a focused symptom, smoking and occupational history, examine for nodes, effusion, collapse, clubbing and metastatic or emergency features, and review prior imaging.
  2. 2Apply current NICE NG12 criteria for urgent radiography or suspected-cancer referral, documenting why persistent concern remains if the initial chest radiograph is normal.
  3. 3Request contrast CT through the lung pathway before invasive sampling unless an emergency or readily accessible metastatic site changes the safest sequence.
  4. 4Give the patient a named contact, safety-net worsening haemoptysis or neurological symptoms, and address distress and smoking support without delaying investigation.
02SAMPLEObtain diagnosis and highest stageCT suggests lung cancer and tissue diagnosis would influence treatment selection.

Risks, monitoring and follow-up

  • Track every referral through radiograph, CT, tissue, pathology, biomarker completion, staging, MDT decision and first treatment, with active escalation of avoidable delay.
  • Review new haemoptysis, dyspnoea, neurological symptoms, bone pain, confusion or facial swelling while investigations proceed because stage and urgency can change quickly.
  • Record pathology adequacy and outstanding PD-L1 or genomic results explicitly; starting non-emergency systemic therapy before decision-changing results may close better options.
  • Reassess performance, nutrition, oxygen needs, analgesia and comorbidity rather than using the state at an acute admission as a permanent fitness judgement.
  • Check that results and MDT decisions reach the patient and primary-care team in plain language with a named contact and agreed next date.
  • Audit whether invasive tests answered both diagnosis and stage; repeated low-yield procedures should prompt pathway redesign, not just individual blame.

Special situations

Biopsy the stage

When a safe distant or nodal target could establish both malignancy and the highest stage, sampling only the primary may expose the patient to another procedure without improving certainty.

CT before the needle

Anatomical mapping before biopsy can reveal a safer target, a different likely diagnosis or disease extent that changes whether invasive confirmation will help.

Negative tests need context

A non-diagnostic biopsy or negative nodal sample lowers risk only according to procedure sensitivity, target selection and adequacy; it never carries one universal meaning.

Tissue is a finite resource

Repeated stains can consume a small sample. Early communication between radiology, respiratory medicine, pathology and oncology preserves material for predictive testing.

Fitness can improve

Treating infection, fluid overload, COPD, malnutrition or deconditioning during staging may turn an apparently unfit patient into a candidate for meaningful treatment.

Support starts at suspicion

Symptom control, smoking support and lung-cancer nursing do not need to wait for final stage; early contact reduces distress and identifies dangerous change.

Common pitfalls

  1. 01

    Dismissing persistent haemoptysis or focal symptoms after one normal chest radiograph despite continued clinical concern.

  2. 02

    Biopsying the easiest-looking primary lesion before CT staging reveals a safer target that could establish metastatic disease simultaneously.

  3. 03

    Requesting serial invasive tests without specifying what a positive, negative or inadequate result would change.

  4. 04

    Using enlarged nodes on CT or FDG uptake alone as definitive malignant mediastinal staging when confirmation could preserve curative treatment.

  5. 05

    Exhausting a small biopsy on classification stains without protecting material for PD-L1 and current genomic testing.

  6. 06

    Waiting for every staging test before treating cord compression, severe metabolic disturbance, major haemoptysis or another oncological emergency.

  7. 07

    Declaring a patient unsuitable from age or an acute performance snapshot without assessing reversible limitations and preferences.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RespiratoryOriginal SBA

Selecting the biopsy target

CT shows a right upper-lobe mass, bulky mediastinal nodes and a safely accessible adrenal lesion in a patient who wants active treatment. Which principle should guide the first tissue procedure?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Respiratory topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG12 Suspected cancer recognition and referralCurrent symptom, imaging and urgent referral criteria for lung cancer.
  • NICE NG122 Diagnosis and stagingCT, biopsy selection, nodal staging, PET-CT and fitness assessment.
  • NICE QS17 Lung cancer quality standardCoordinated diagnosis, staging, information and specialist support.
  • NHS England National Genomic Test DirectoryCurrent genomic tests commissioned for cancer pathways.
  • NHS England National Genomic Test Directory overviewGovernance and updating of nationally available genomic testing.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Assess performance status, comorbidity, lung function, frailty and the patient's priorities in parallel with diagnosis, while urgently treating haemoptysis, superior vena cava obstruction or spinal cord compression.
  • New limb weakness, sphincter change or severe spinal pain suggests metastatic cord compression and requires the emergency pathway without waiting for lung histology.
  • Facial and upper-limb swelling with venous distension suggests superior vena cava obstruction; assess airway or cerebral compromise urgently and coordinate imaging and tissue with oncology.
  • Confusion, dehydration or arrhythmia with hypercalcaemia, or seizures with severe hyponatraemia, needs acute metabolic management while the underlying cancer is investigated.
  • Do not delay a time-critical emergency treatment solely to obtain an ideal biopsy, but whenever feasible secure diagnostic tissue before therapy that could erase pathological yield.
    • FDG PET-CT
    Why
    Identify metabolically suspicious nodal or distant disease when treatment intent may be curative.
    Interpretation and limitations
    Confirm findings that would deny curative therapy when feasible because infection and inflammation can be avid; small-volume or low-metabolic disease may be missed.
  • 06
    Brain imaging
    Why
    Detect intracranial metastases when symptoms, histology, stage or planned treatment justify it.
    Interpretation and limitations
    MRI is more sensitive when available; select it according to the NICE staging pathway and do not omit urgent imaging for new neurological features.
  • 07
    Pulmonary and functional assessment
    Why
    Estimate ability to tolerate resection, radiotherapy or systemic treatment.
    Interpretation and limitations
    Combine spirometry, gas transfer, exercise assessment when needed, cardiac risk, performance status and frailty; chronological age alone does not define treatment fitness.
  • 08
    PD-L1 and genomic testing
    Why
    Identify predictive biomarkers that select current NSCLC systemic therapies.
    Interpretation and limitations
    Use the current NHS Genomic Test Directory and NICE technology appraisals because required genes and funded indications evolve; test quality and tumour cellularity matter.
    • +
    1. 1Define the questions before the procedure: histological type, highest anatomical stage and quantity needed for immunohistochemistry, PD-L1 and genomic analysis.
    2. 2Select the least invasive, highest-yield target that can diagnose and stage, prioritising an accessible metastatic lesion or suspicious node when appropriate.
    3. 3Use bronchoscopy for suitable central or bronchus-sign lesions, EBUS or EUS for nodes, and image-guided biopsy for an accessible peripheral target, with risks explained.
    4. 4If tissue is inadequate or discordant, review procedure yield and residual probability at MDT to choose repeat sampling, another target or a treatment decision based on all evidence.
    03STAGEComplete decision-changing stagingPathology or very high clinical suspicion establishes a potentially treatable primary lung cancer.+
    1. 1Assign provisional TNM stage from CT and pathology, then use PET-CT when curative treatment remains possible and extracranial staging will affect intent.
    2. 2Confirm suspicious mediastinal nodes or a solitary distant focus pathologically when feasible if that result would remove a potentially curative option.
    3. 3Select brain imaging from neurological symptoms, histology, clinical stage and treatment intent, using MRI when the pathway requires sensitive intracranial assessment.
    4. 4Present stage, histology, biomarkers and uncertainty together at MDT rather than issuing disconnected results that do not resolve a treatment choice.
    04FITNESSAssess treatment capacity in parallelA potentially curative or disease-controlling treatment option is being considered.+
    1. 1Document performance status, frailty, comorbidity, cognition, social support and the patient's priorities without treating smoking or age as automatic exclusion criteria.
    2. 2Measure spirometry and gas transfer for local treatment planning, adding exercise or cardiac assessment when initial results or the proposed resection warrant it.
    3. 3Optimise COPD, nutrition, anaemia, medications and physical function while molecular tests and staging proceed, avoiding sequential delay.
    4. 4Explain realistic treatment options and supportive care early, arranging lung-cancer nursing, symptom control and palliative-care input according to need rather than prognosis alone.